Where&#x27;s your evidence for these high co-pays that Turing did not subsidize? I searched both transcripts for &quot;co-pay&quot; and &quot;mortgage,&quot; and didn&#x27;t find anything like what you&#x27;re claiming. In fact, I see the opposite. I see the CEO of Turing being cross-examined by a hostile Massachusetts congressman accusing her of causing $6000 co-pays. She says, no, we paid anyone directly who fell through the cracks in this way. He replies, &quot;after 4 days.&quot;<p>Searching for the word &quot;mortgage&quot; yielded no results for me.<p>I used to think drug companies were a scourge. After researching the Shkreli controversy last year I&#x27;m not so sure. But Shkreli, with his (often funny) dickhead antics, certainly would be a convenient whipping boy -- if anyone, like Congress or special interests -- needed a whipping boy to distract the public from what&#x27;s actually ailing American health care.<p>For some perspective, drugs are only 1&#x2F;10 of American health care costs.<p><pre><code>  Prescription drugs: 10%
  Dental care: 4%
  Hospital care: 32%
  Physician&#x2F;clinical services: 20%
  
  Source: https:&#x2F;&#x2F;www.cms.gov&#x2F;Research-Statistics-Data-and-Systems&#x2F;Statistics-Trends-and-Reports&#x2F;NationalHealthExpendData&#x2F;Downloads&#x2F;PieChartSourcesExpenditures2014.pdf
</code></pre>
And as far as Shkreli goes, the reality, as far as I&#x27;ve seen so far, is that no one is paying these sky-high prices for Daraprim out of pocket. Check out Turing&#x27;s 10-K&#x27;s; they reinvest their profits in R+D. Shkreli himself seems to be legitimately interested in developing new and better treatments for rare diseases. (CMD+F: &quot;PKAN&quot; on this page: <a href="http:&#x2F;&#x2F;www.bloomberg.com&#x2F;news&#x2F;articles&#x2F;2014-04-17&#x2F;retrophins-martin-shkreli-the-biotech-short-seller-who-went-long" rel="nofollow">http:&#x2F;&#x2F;www.bloomberg.com&#x2F;news&#x2F;articles&#x2F;2014-04-17&#x2F;retrophins...</a>)<p>Serious question. For these super-rare diseases like toxoplasmosis, the current profit model is this. First, charge a high price ($30k-$100k) for a course of treatment. Then, the few people suffering from the rare disease get the drug via insurance. Does anyone have a better way of incentivizing drug companies to create new treatments, or better treatments, for rare diseases?